Q2 2023 ImmuCell Corporation Earnings Call

Good day and welcome to the <unk> Corporation second quarter fiscal year, 2023 financial results conference call.

All participants will be in a listen only mode.

You need assistance. Please signal a conference specialist by pressing the star key followed by zero.

After todays presentation, there will be an opportunity to ask questions.

To ask a question you May press Star then one on the Touchtone phone.

To withdraw your question. Please press Star then two.

Note. This event is being recorded.

I would now like to turn the conference over to Joe Dormie with Boston Partners. Please go ahead.

Thank you good morning, and welcome Betsy indicated my name is Joe Gourmet with Lytham partners, we are the Investor relations consulting firm for himself.

Thank you.

As I indicated that we will be discussing and yourselves unaudited financial results for the quarter ended June 32023.

With us today on the call is Michael Brigham President and CEO .

After the conclusion of today's prepared remarks, we'll open the call for questions.

Before we begin with prepared remarks, I would like to remind everyone. Certain statements made by management. During this conference call include forward looking statements, which include any statements that refer to future events or expected future events or predictions about that's the company plans to take in the future.

These statements are not guarantees of performance and are subject to risks and uncertainties that could cause actual results outcomes or events to differ materially from those discussed today.

Additional information regarding forward looking statements and the risks and uncertainties that could impact future results outcomes or event is available on the cautionary note regarding forward looking statements or the safe Harbor statement provided in the quarterly report on Form 10-Q that the company filed last night, along with the company's other periodic file.

With the Securities and Exchange Commission information discussed on today's call speaks only as of today Friday August 11, 2023. The company undertakes no obligation to update any information discussed on today's call.

Please note that references to certain non-GAAP financial measures, which may be made during today's call.

Company included definitions of these terms as well as reconciliations of these figures and the most comparable GAAP financial measures and last Night's press release in order to better assist you in understanding its financial performance now I'd like to turn the call over to Michael Brigham President and CEO of immune cell Michael.

Great. Thanks, Joe and good morning, everyone. Our first one with regards to the financial results last Night's press release reports no change to our product sales.

That were first reported on July 11th the press release also provides the full unaudited P&L results and some auto unaudited summary balance sheet data.

We also filed our Form 10-Q for the quarter ended June 32023 last night I won't take your time here to review those financial results in detail.

Last Night's press release also includes our non-GAAP earnings before income taxes, depreciation and amortization or EBITDA. Please see page five for that you can see a significant swing of $3 4 million from positive EBITDA of $1 2 million during the six months ended June 32022.

To negative EBITDA of $2 2 million during the six months ended June 32023, this negative swing in EBITDA pretty much matches, a $3 5 million dollar increase in our net loss from a loss of 171000. During the six months ended June 32022 to a loss of $3 7 million.

During the six months ended June 32023, the increase in the net loss was in turn largely caused by the $3 5 million decrease in gross margin earned.

From $4 8 million during the six months ended June 30, 22 to $1 3 million during the six months ended June 32023.

So what is going on here.

Let me try and speak to that first of all we're very fortunate to have the support of our partners that Gorham savings bank in the finance authority of Maine through a combined combined $3 million of debt facility that we closed in July this was very important to our cash flows.

I would like to point you to a disclosure on page 30 quarterly report under the heading production capacity increase product contamination and related events in which we review some of the significant challenges we have faced over the last 12 months that contributed to our current financial results.

I would like to discuss some of these changes here.

So as of July 2022, we have completed almost all of the facility expansion work in new equipment installations needed to significantly increase our production capacity. However, the most critical piece of new equipment being Freeze-dry number four was delivered six months late by the fabricator.

This caused us only six months to our plan, but by the end of 2022, we have freeze dryer number four approved for use by the U S. T E G.

Just as we began to operate at this higher level of capacity at the beginning of 2023, we were forced to slow down production to remediate a contamination event related to our incoming raw material at the same time freeze dryer number two stopped operating requiring a six month repair netting us back to three operating freeze dryers.

Yeah.

As of early July 2023, we are back to operating for freeze dryers and the contamination event was largely behind us.

Keep more of that remediation in just a moment.

Then during the second week of July 2023, USDA arrived on site to conduct a routine routine unannounced inspection and we were required to divert much of our quality and manufacturing personnel to support this inspection totally could promptly submit our detailed responses to the inspection observations to the USDA.

As we were preparing our responses under the timeline agreed with the USDA. The USDA impose a voluntary stopped distribution and sale of V. S. D. S order.

The holder of Nissan first events until two of the inspection observations were resolved. This meant we were prohibited from shipping product beginning with the week of July 24th and continuing until at least two inspection observations were resolved.

It's important to note that we were not prohibited from continuing to produce inventory during this period.

As of August 4th the USDA had verbally rescinded the V. S T S and the whole release, allowing us to return to near normal shipping conditions.

Since then that verbal resend has been updated in writing.

Despite this significant diversion of our resources, we anticipate that we will make our third submission of the CMC technical section for retaining to the FDA shortly.

This submission will be subject to a six month review by the FDA, we remain poised and excited to revolutionize the way that subclinical mastitis is treated in today's dairy market with a novel alternative to traditional antibiotics.

As I said the last 12 months have been very challenging for us for sure. We have worked incredibly hard to address these challenges and move forward based on our responses I am optimistic, but what we can do in the coming quarters.

But let's go back to the contamination comment I'd like to make an additional comment about the remediation of the contamination events. So we have been driven by data.

Resolve this temporary production problem I'd like to explain what I mean by that all production batches are routinely tested by our quality control team at the beginning middle and end of the production process. During the four month period ended August 4th.

All three of these standard quality control tests have met specifications, 100% of the time improvements throughout the production process from the depth of the contamination problem in January are allowing us to come back into full production.

We believe that the operational improvements we have implemented.

Help us run more effectively and higher output level going forward. Our goal is to be able to produce about $6 million worth of product per quarter, which would annualize to about 80% of our estimated 30 million full production capacity annually.

So lastly, I'd like to encourage you to review the press release and the quarterly report that we filed last night also please have a look at our corporate presentation slide deck I believe it provides a very good summary of our business strategy and objectives as well as our current financial results in August update was just posted to our website last night.

See the investors section on our website and click on corporate presentation or contact us for a copy.

With that said I'd be happy to take your questions, let's have Betsy open up the lines.

We will now begin the question and answer session.

Asked a good question you May Press Star then one on your Touchtone phone.

If you are using a speakerphone please pick up your handset before pressing the keys.

If at any time. Your question has been addressed and you would like to withdraw your question. Please press Star then two.

Once again, that's star then one to ask a question.

At this time, we will pause momentarily to assemble our roster.

As a reminder, if you have a question. Please press star and one can be joined into the question queue.

This concludes our question and answer session I would like to turn the conference back over to Joe Thomas for any closing remarks.

Yeah.

We would like to thank you for participating in today's call. We look forward to talking with you again, when we host our third quarter call on or about Tuesday November 14th 2023 and have a great day.

The conference has now concluded. Thank you for attending today's presentation you may now disconnect.

[music].